A Phase 3 interventional study of Rotigotine and Placebo in Parkinson's Disease, sponsored by UCB Pharma. Completed at 47 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-22.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.
Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 10th largest by enrollment of the 42 interventional ones that give a count, is one of 6 that started in 2007, is one of 20 in phase 3, and was the 7th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:
Eva Pharma
Ages 30+
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 22 · Phase 4 8
First in 1999; this study’s year is marked. 6 started in 2007.
This study's enrollment of 287 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 123 across the 42 interventional studies. Of the 41 that completed or were terminated, 30 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
44 studies in Parkinson Disease by UCB S.A.: none open now, none under way, none of them phase 3. Of 44 finished, 29 (66%) have results posted.
Among the 44 studies in Parkinson Disease by UCB S.A., this one is the 10th largest by enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2007, is one of 19 in phase 3, and was the 10th registered.
UCB S.A.’s Parkinson Disease studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing rotigotine in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 44 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this trial is to assess the effects of transdermal rotigotine on the control of early morning motor function and sleep disorders compared to placebo in subjects with idiopathic Parkinsons´s disease. In addition, effects of rotigotine on specific nocturnal and non-motor symptoms of Parkinson´s disease will be evaluated.
The objective of this trial is to assess the effects of rotigotine on the control of early morning motor function and sleep disorders compared to placebo in subjects with idiopathic Parkinsons´s disease. In addition, effects of rotigotine on specific nocturnal and non-motor symptoms of Parkinson´s disease will be evaluated.
After a Screening Period of up to 28 days subjects will be hospitalized for two nights. After the second overnight stay, subjects will be randomly assigned either to rotigotine patch or placebo patch. Afterwards patients will be titrated to their optimal dose. After subjects have reached their optimal dose (or the highest dose) they will be maintained on this dose for a certain period. At the end of maintenance the subjects will be hospitalized for two nights. Afterwards the doses will be continuously decreased.
Efficacy will be assessed by application of sleep quality scores, motor examination scores, and scores to evaluate non-motor symptoms of Parkinsons. Safety assessments include adverse events, 12-lead electrocardiograms, blood pressure and heart rate assessments, and laboratory checks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Rotigotine transdermal patch
Drug: Rotigotine
Placebo transdermal patch
Other: Placebo
Rotigotine transdermal patches: 10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h) Optimal dosing: The maximum Rotigotine dose allowed is 16mg/24h
Also known as: Neupro
Placebo transdermal patches
Change in Early Morning UPDRS Part III Score
The Unified Parkinson´s Disease Rating Scale Part III score is an accepted and validated sumscore of 14 items for the assessment of motor function in Parkinson´s disease. Each of the 14 items in the UPDRS part III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities.
Time frame: From baseline to end of maintenance (after 4 weeks maintenance)
Change in Parkinson's Disease Sleep Scale (PDSS)
The Parkinson´s Disease Sleep Scale (PDSS) is a questionnaire with 15 questions to assess sleep and nocturnal disability in Parkinson´s disease. The item- scores can range between 0= never and 4= very often. The PDSS score is a sumscore of all 15 questions.
Time frame: From baseline to end of maintenance (after 4 weeks maintenance)
Change in Nocturnal Akinesia, Dystonia, and Cramps Score (NADCS)
Subjects were asked to assess nocturnal akinesia, dystonia and cramps, using an ordinal severity scale. While a score of 0= normal and 4= maximal severity, subjects could also rate their symptoms with values of 0.5, 1.5, 2.5, 3.5. The nocturnal akinesia score was used to evaluate motor performance while the dystonia and cramps scores were used to evaluate sleep.
Time frame: From baseline to end of maintenance (after 4 weeks maintenance)
Change in Number of Nocturias
Nocturia is the need to get up during the night and interrupt sleep in order to urinate. It is a typical nocturnal symptom of Parkinson´s disease. The change from baseline in number of nocturias was used to evaluate improvements in sleep disorders.
Time frame: From baseline to end of maintenance (after 4 weeks maintenance)
A total of 333 subjects were enrolled in this trial and comprised the Enrolled Set (ES). 287 subjects were randomized and all of them received at least 1 dose of trial medication, so they all belong to the Safety Set (SS). 267 subjects belong to the Full Analysis Set (FAS).
| Milestone | Rotigotine | Placebo |
|---|---|---|
| Started | 190 | 97 |
| Completed | 166 | 80 |
| Not completed | 24 | 17 |
| Withdrew: Adverse event | 11 | 6 |
| Withdrew: Lack of efficacy | 0 | 4 |
| Withdrew: Withdrawal by subject | 11 | 7 |
| Withdrew: Other | 2 | 0 |
The Unified Parkinson´s Disease Rating Scale Part III score is an accepted and validated sumscore of 14 items for the assessment of motor function in Parkinson´s disease. Each of the 14 items in the UPDRS part III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities.
| units on a scale | Rotigotine | Placebo |
|---|---|---|
| Change in Early Morning UPDRS Part III Score | -7.0 ± 7.6 | -3.9 ± 7.3 |
The Parkinson´s Disease Sleep Scale (PDSS) is a questionnaire with 15 questions to assess sleep and nocturnal disability in Parkinson´s disease. The item- scores can range between 0= never and 4= very often. The PDSS score is a sumscore of all 15 questions.
| units on a scale | Rotigotine | Placebo |
|---|---|---|
| Change in Parkinson's Disease Sleep Scale (PDSS) | -5.9 ± 7.6 | -1.9 ± 8.2 |
Subjects were asked to assess nocturnal akinesia, dystonia and cramps, using an ordinal severity scale. While a score of 0= normal and 4= maximal severity, subjects could also rate their symptoms with values of 0.5, 1.5, 2.5, 3.5. The nocturnal akinesia score was used to evaluate motor performance while the dystonia and cramps scores were used to evaluate sleep.
| units on a scale | Rotigotine | Placebo |
|---|---|---|
| Change in Nocturnal Akinesia, Dystonia, and Cramps Score (NADCS) | -1.3 ± 1.8 | -0.9 ± 2.1 |
Nocturia is the need to get up during the night and interrupt sleep in order to urinate. It is a typical nocturnal symptom of Parkinson´s disease. The change from baseline in number of nocturias was used to evaluate improvements in sleep disorders.
| nocturias | Rotigotine | Placebo |
|---|---|---|
| Change in Number of Nocturias | -0.3 ± 1.3 | -0.2 ± 1.1 |
Collected over Adverse Events (AEs) were collected up to 22 weeks from Visit 1 to the Safety Follow- Up Visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rotigotine | — | 10/191 (5.2%) | 70/191 (36.6%) |
| Placebo | — | 5/96 (5.2%) | 21/96 (21.9%) |
| Event | Rotigotine | Placebo |
|---|---|---|
| Oedema peripheralGeneral disorders | 0/191 | 1/96 |
| Chronic lymphocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/191 | 1/96 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/191 | 1/96 |
| Cerebrovascular accidentNervous system disorders | 0/191 | 1/96 |
| Panic attackPsychiatric disorders | 0/191 | 1/96 |
| Completed suicidePsychiatric disorders | 0/191 | 1/96 |
| Nephrotic syndromeRenal and urinary disorders | 0/191 | 1/96 |
| Renal impairmentRenal and urinary disorders | 0/191 | 1/96 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 0/191 | 1/96 |
| DiarrhoeaGastrointestinal disorders | 1/191 | 0/96 |
| Event | Rotigotine | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 41/191 | 9/96 |
| DizzinessNervous system disorders | 20/191 | 6/96 |
| DyskinesiaNervous system disorders | 15/191 | 4/96 |
| HeadacheNervous system disorders | 13/191 | 5/96 |
| Age, Categorical(Participants) | Rotigotine | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 87 | 40 | 127 |
| >=65 years | 91 | 49 | 140 |
| Age, Continuous(years) | Rotigotine | Placebo | Total |
|---|---|---|---|
| Mean | 64.7 ± 9.4 | 64.5 ± 10.4 | 64.6 ± 9.7 |
| Sex: Female, Male(Participants) | Rotigotine | Placebo | Total |
|---|---|---|---|
| Female | 61 | 31 | 92 |
| Male | 117 | 58 | 175 |
| Race (NIH/OMB)(Participants) | Rotigotine | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 164 | 79 | 243 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 11 | 8 | 19 |
| Body Mass Index (BMI)(kg/ m^2) | Rotigotine | Placebo | Total |
|---|---|---|---|
| Mean | 26.676 ± 4.164 | 26.645 ± 4.569 | 26.665 ± 4.295 |
| Height(cm) | Rotigotine | Placebo | Total |
|---|---|---|---|
| Mean | 169.04 ± 9.11 | 170.73 ± 9.27 | 169.60 ± 9.18 |
| Weight(kg) | Rotigotine | Placebo | Total |
|---|---|---|---|
| Mean | 76.6 ± 15.1 | 78.0 ± 16.2 | 77.1 ± 15.5 |
The record gives a start of May 2007, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine